OncClubAll Oncology News
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid Readouts
Conference CoverageConference Listing
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
PartnersPublications
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker ConsortiumSubscribe
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Spotlight -
  • The OncLive Insider app is live!
  • CME Opportunities
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
    • Partners
    • Publications
    • Biomarker Consortium
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Metastatic Melanoma: The New Millennium

home / peer-exchange / advances-in-melanoma
Systemic Therapy with T-VEC in Advanced Melanoma

EP. 1: Systemic Therapy with T-VEC in Advanced Melanoma

December 16th 2015
Practical Application of T-VEC in Melanoma Treatment

EP. 2: Practical Application of T-VEC in Melanoma Treatment

December 16th 2015
Radiation Therapy and Abscopal Effect in Melanoma Treatment

EP. 3: Radiation Therapy and Abscopal Effect in Melanoma Treatment

December 16th 2015
Role of Surgery in the Management of Advanced Melanoma

EP. 4: Role of Surgery in the Management of Advanced Melanoma

December 16th 2015
Use of Immunotherapy Agents in Melanoma Treatment

EP. 5: Use of Immunotherapy Agents in Melanoma Treatment

December 16th 2015
Sequencing of Checkpoint Agents in Melanoma

EP. 6: Sequencing of Checkpoint Agents in Melanoma

December 16th 2015
Duration of Immunotherapy in Melanoma

EP. 7: Duration of Immunotherapy in Melanoma

December 16th 2015
Checkpoint Inhibitors: Combination Therapy in Melanoma

EP. 8: Checkpoint Inhibitors: Combination Therapy in Melanoma

December 16th 2015
Combination Immunotherapy Treatment Duration in Melanoma Patients

EP. 9: Combination Immunotherapy Treatment Duration in Melanoma Patients

December 16th 2015
Treatment of BRAF-Mutant Metastatic Melanoma

EP. 10: Treatment of BRAF-Mutant Metastatic Melanoma

December 16th 2015
Sequencing Dual BRAF-MEK Inhibition and Immunotherapy

EP. 11: Sequencing Dual BRAF-MEK Inhibition and Immunotherapy

December 16th 2015
Duration of Dual BRAF-MEK Inhibition in Melanoma

EP. 12: Duration of Dual BRAF-MEK Inhibition in Melanoma

December 16th 2015
Hot Versus Cold Tumors: Predictive Markers in Melanoma

EP. 13: Hot Versus Cold Tumors: Predictive Markers in Melanoma

December 16th 2015
Future Advances in Melanoma Treatment

EP. 14: Future Advances in Melanoma Treatment

December 16th 2015

Latest Conference Coverage

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer

Raludotatug Deruxtecan Shows Activity in Platinum-Sensitive Ovarian Cancer

Relacorilant/Nab-Paclitaxel Is Associated With Survival Improvement in Platinum-Resistant Ovarian Cancer After Short Platinum-Free Interval

PD-L1 CPS Does Not Enrich the Efficacy of Atezolizumab/Bevacizumab and Chemo in Advanced Cervical Cancer

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Download on Apple
© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact